Transplantation, AutologousHematopoietic Stem Cell TransplantationStem Cell TransplantationTransplantation, HomologousPeripheral Blood Stem Cell TransplantationTransplantation ConditioningMultiple MyelomaMelphalanStem CellsAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyTreatment OutcomeRemission InductionGraft vs Host DiseaseSalvage TherapyLymphoma, Non-HodgkinDisease-Free SurvivalMyeloablative AgonistsHodgkin DiseaseRecurrenceEtoposideCyclophosphamideBone Marrow TransplantationLymphomaHematologic NeoplasmsCytarabineHematopoietic Stem Cell MobilizationSurvival RateCarmustineHematopoietic Stem CellsVincristineSurvival AnalysisLymphoma, Mantle-CellThiotepaBone Marrow PurgingBusulfanWhole-Body IrradiationRetrospective StudiesLymphoma, FollicularGraft SurvivalAmyloidosisPrognosisAntibodies, Monoclonal, Murine-DerivedBoronic AcidsTransplantation ChimeraLymphoma, B-CellDexamethasoneDoxorubicinLymphoma, T-Cell, PeripheralPyrazinesAntigens, CD34Lymphoma, Large B-Cell, DiffuseFollow-Up StudiesMesenchymal Stem Cell TransplantationAntineoplastic Agents, AlkylatingThalidomideTissue DonorsAutograftsTime FactorsLiver TransplantationEmbryonic Stem CellsNeoplasm, ResidualGranulocyte Colony-Stimulating FactorLeukemia, Myeloid, AcuteAntineoplastic AgentsPrednisoneIfosfamideLeukapheresisAdult Stem CellsCord Blood Stem Cell TransplantationInduction ChemotherapyPodophyllotoxinMyelodysplastic SyndromesGraft vs Leukemia EffectHistocompatibility TestingMaintenance ChemotherapyImmunosuppressive AgentsCell TransplantationVidarabineLeukemiaCell DifferentiationEnteropathy-Associated T-Cell LymphomaPluripotent Stem CellsKidney TransplantationGraft vs Tumor EffectIdarubicinHistocompatibilityMesenchymal Stromal CellsMitoxantroneAntibodies, MonoclonalNeoplasms, Second PrimaryProspective StudiesLeukemia, Plasma CellInfusions, SpinalLeukemia, MyeloidStem Cell NicheBlood Component RemovalFatal OutcomeT-LymphocytesNeural Stem Cells